Vertex, Inc. is rated a Buy due to steady growth, margin expansion, recurring revenue, and high retention. Learn more about ...
Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Click for this earnings preview of VRTX stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results